



In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to therapeutic levels of taxanes for several weeks, causes a sustained tumoricidal response, produces clinical benefits without local or systemic toxicity, and may facilitate treatment of metastatic disease.

Clinical Stage Oncology Company



NanOlogy Submicron Particle Therapeutic Platform

Novel formulations offer range of therapeutic options



Promising Preclinical/Clinical Data

Pancreatic Neoplasms	- Evidence of tumor volume reduction, biomarker reduction - MCN/IPMN volume reduction - No drug-related SAEs including no pancreatitis - Pivotal clinical trial in LAPC planned	Prostate Cancer	- Evidence of tumor volume reduction and PSA-density decrease - No drug-related SAEs including no prostatitis - Follow-on trial expected to enroll first patient in early 2020
Bladder Cancer	- Clever 2-arm design evaluating both BMIBC and MIBC - No drug-related SAEs allowing escalation to highest dose in both arms - Preliminary data expected mid-year	Other Highlights	- Encouraging PFS data in ovarian clinical trial - Lung IND submissions planned for direct injection and inhalation of NanoPac - Increased immune response versus IV comparators across multiple tumors types in xenograft and syngeneic animal models

NanOlogy Development Pipeline

Product	Indication	Delivery	Preclinical	Phase 1	Phase 2	Phase 3
NanoPac® for Suspension Sterile Submicron Particle Paclitaxel	Locally Advanced Pancreatic Adenocarcinoma	Intratumoral	→	→	→	
	Mucinous Cystic Pancreatic Neoplasms	Intracystic	→	→	→	
	Peritoneal Malignancies/Ovarian Cancer	Intraperitoneal	→	→	→	
	Prostate Cancer	Intratumoral	→	→	→	
NanoDoce® for Suspension Sterile Submicron Particle Docetaxel	High Risk Non-Muscle Invasive Bladder Cancer	Resection Bed Injection Intravesical Instillation	→	→		
	Muscle Invasive Bladder Cancer	Resection Bed Injection Intravesical Instillation	→	→		
	Renal Cell Carcinoma	Intratumoral	→	→		
NanoPac® for Nebulized Inhalation Submicron Particle Paclitaxel	Non-Small Cell Lung Cancer	Direct Injection/ Inhalation	→			
NanoPac® Topical (SOR007) Submicron Particle Paclitaxel Ointment	Cutaneous Metastases	Topical	→	→	→	

NanOlogy Management Team

H. Paul Dorman, Chairman & CEO
Gere diZerega, MD, Chief Medical Officer
Mark Mitchell, Chief Legal Officer
Maxwell Lea, Managing Director
Marc Iacobucci, Managing Director

NanOlogy Advisors

Ashish Kamat, MD Anderson Cancer Center
Donald Lamm, BCG Oncology
Julie Lang, USC Keck School of Medicine
Maurie Markman, Cancer Treatment Centers of America
Mohamed Othman, Baylor College of Medicine

Publications & Presentations

Genitourinary Preclinical Abstract
 ASCO-GU February 2019
Lung Preclinical Abstract
 ATS May 2019
NSCLC Journal Article
 JAMPDD August 2019
Pancreatic Cancer Plenary Presentation
 ACG October 2019
Pancreatic Cystic Neoplasms Abstract
 ACG October 2019



Marc Iacobucci - marc.iacobucci@dfb.com; +817-916-2247
 Maxwell Lea - maxwell.lea@dfb.com; +817-900-4084
 NanOlogy, LLC 3909 Hulen Street, Fort Worth, TX 76107 USA
 www.nanology.us